PH12012501516A1 - Radioimmunoconjugates and uses thereof - Google Patents
Radioimmunoconjugates and uses thereofInfo
- Publication number
- PH12012501516A1 PH12012501516A1 PH1/2012/501516A PH12012501516A PH12012501516A1 PH 12012501516 A1 PH12012501516 A1 PH 12012501516A1 PH 12012501516 A PH12012501516 A PH 12012501516A PH 12012501516 A1 PH12012501516 A1 PH 12012501516A1
- Authority
- PH
- Philippines
- Prior art keywords
- radioimmunoconjugates
- present
- radioimmunoconjugate
- cancer
- aspects
- Prior art date
Links
- 229940051022 radioimmunoconjugate Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000048426 human CD37 Human genes 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29952410P | 2010-01-29 | 2010-01-29 | |
| NO20100143A NO331080B1 (no) | 2010-01-29 | 2010-01-29 | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| PCT/EP2011/051231 WO2011092295A2 (en) | 2010-01-29 | 2011-01-28 | Novel radioimmunoconjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012501516A1 true PH12012501516A1 (en) | 2024-04-03 |
Family
ID=44319900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/501516A PH12012501516A1 (en) | 2010-01-29 | 2011-01-28 | Radioimmunoconjugates and uses thereof |
| PH12017501038A PH12017501038B1 (en) | 2010-01-29 | 2017-06-05 | Novel radioimmunoconjugates and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017501038A PH12017501038B1 (en) | 2010-01-29 | 2017-06-05 | Novel radioimmunoconjugates and uses thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8628749B2 (enExample) |
| EP (2) | EP2705857B1 (enExample) |
| JP (2) | JP5646652B2 (enExample) |
| KR (2) | KR101893720B1 (enExample) |
| CN (2) | CN104338154B (enExample) |
| AU (1) | AU2011209441B2 (enExample) |
| BR (1) | BR112012018843B8 (enExample) |
| CA (1) | CA2786655C (enExample) |
| DK (2) | DK2705857T3 (enExample) |
| ES (2) | ES2469140T3 (enExample) |
| HR (1) | HRP20140538T1 (enExample) |
| IL (2) | IL221091A (enExample) |
| MX (2) | MX342539B (enExample) |
| NO (1) | NO331080B1 (enExample) |
| NZ (1) | NZ601055A (enExample) |
| PH (2) | PH12012501516A1 (enExample) |
| PL (1) | PL2528627T3 (enExample) |
| PT (1) | PT2528627E (enExample) |
| RS (1) | RS53346B (enExample) |
| RU (2) | RU2560587C9 (enExample) |
| SG (1) | SG182685A1 (enExample) |
| SI (1) | SI2528627T1 (enExample) |
| UA (1) | UA108631C2 (enExample) |
| WO (1) | WO2011092295A2 (enExample) |
| ZA (1) | ZA201205007B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203372A1 (en) * | 2011-12-13 | 2015-10-30 | Nordic Nanovector Asa | Chimeric therapeutic anti - cd37 antibodie hh1 |
| US20150093397A1 (en) * | 2012-03-30 | 2015-04-02 | Immunogen, Inc. | Methods for Increasing Efficacy of CD37-Based Therapy |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| EP3332813B1 (en) * | 2013-06-07 | 2019-05-29 | Nordic Nanovector ASA | Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody |
| AU2014296219A1 (en) | 2013-08-01 | 2016-02-25 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to CD37 proteins |
| BR112017020689A2 (en) * | 2015-04-07 | 2018-06-26 | Memorial Sloan-Kettering Cancer Center | nanoparticulate immunoconjugates |
| GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| JP2019529433A (ja) * | 2016-09-16 | 2019-10-17 | ノルディック ナノベクター アルメン アクスイェ セルスカプ | リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 |
| KR102406510B1 (ko) | 2017-07-03 | 2022-06-10 | 현대자동차주식회사 | 연료전지 시스템용 수소 공급 방법 |
| CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
| US20210106703A1 (en) * | 2017-11-22 | 2021-04-15 | Nordic Nanovector Asa | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| CA3137568A1 (en) * | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| CN117241832A (zh) * | 2021-03-19 | 2023-12-15 | 海德堡医药研究有限责任公司 | B淋巴细胞特异性的鹅膏毒素抗体缀合物 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| US20250333531A1 (en) | 2021-10-06 | 2025-10-30 | Nordic Nanovector Asa | Humanized hh1 |
| CN114081969A (zh) * | 2021-11-23 | 2022-02-25 | 成都纽瑞特医疗科技股份有限公司 | 标记的小分子抗体、及其标记方法和应用 |
| CN117285631A (zh) * | 2023-11-24 | 2023-12-26 | 原子高科股份有限公司 | 用于放射性免疫治疗的Lu-177标记MUC1抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| MXPA02010507A (es) * | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| RU2005122033A (ru) * | 2002-12-13 | 2006-01-27 | Митра Медикал Текнолоджи Аб (Se) | Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| EP1587550B1 (en) * | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| WO2005084179A2 (en) * | 2003-12-01 | 2005-09-15 | Immunomedics, Inc. | Improved method for preparing conjugates of proteins and chelating agents |
| HUE026303T2 (hu) * | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
-
2010
- 2010-01-29 NO NO20100143A patent/NO331080B1/no not_active IP Right Cessation
-
2011
- 2011-01-28 CN CN201410353070.5A patent/CN104338154B/zh active Active
- 2011-01-28 PL PL11700972T patent/PL2528627T3/pl unknown
- 2011-01-28 CN CN201180007272.9A patent/CN102762230B/zh not_active Expired - Fee Related
- 2011-01-28 CA CA2786655A patent/CA2786655C/en active Active
- 2011-01-28 JP JP2012550464A patent/JP5646652B2/ja not_active Expired - Fee Related
- 2011-01-28 NZ NZ601055A patent/NZ601055A/en not_active IP Right Cessation
- 2011-01-28 PH PH1/2012/501516A patent/PH12012501516A1/en unknown
- 2011-01-28 BR BR112012018843A patent/BR112012018843B8/pt not_active IP Right Cessation
- 2011-01-28 ES ES11700972.0T patent/ES2469140T3/es active Active
- 2011-01-28 UA UAA201208485A patent/UA108631C2/ru unknown
- 2011-01-28 DK DK13195682.3T patent/DK2705857T3/en active
- 2011-01-28 EP EP13195682.3A patent/EP2705857B1/en active Active
- 2011-01-28 MX MX2015000391A patent/MX342539B/es unknown
- 2011-01-28 KR KR1020177018914A patent/KR101893720B1/ko not_active Expired - Fee Related
- 2011-01-28 RU RU2012135430/10A patent/RU2560587C9/ru active
- 2011-01-28 RS RS20140300A patent/RS53346B/sr unknown
- 2011-01-28 PT PT117009720T patent/PT2528627E/pt unknown
- 2011-01-28 RU RU2015127407A patent/RU2664475C1/ru active
- 2011-01-28 KR KR1020127020917A patent/KR101758409B1/ko not_active Expired - Fee Related
- 2011-01-28 SI SI201130157T patent/SI2528627T1/sl unknown
- 2011-01-28 HR HRP20140538AT patent/HRP20140538T1/hr unknown
- 2011-01-28 WO PCT/EP2011/051231 patent/WO2011092295A2/en not_active Ceased
- 2011-01-28 EP EP11700972.0A patent/EP2528627B1/en active Active
- 2011-01-28 SG SG2012054607A patent/SG182685A1/en unknown
- 2011-01-28 ES ES13195682.3T patent/ES2592402T3/es active Active
- 2011-01-28 AU AU2011209441A patent/AU2011209441B2/en not_active Ceased
- 2011-01-28 DK DK11700972.0T patent/DK2528627T3/da active
- 2011-01-28 MX MX2012008695A patent/MX2012008695A/es active IP Right Grant
- 2011-01-28 US US13/522,678 patent/US8628749B2/en active Active
-
2012
- 2012-07-04 ZA ZA2012/05007A patent/ZA201205007B/en unknown
- 2012-07-24 IL IL221091A patent/IL221091A/en active IP Right Grant
-
2013
- 2013-12-09 US US14/100,756 patent/US9358309B2/en active Active
-
2014
- 2014-11-05 JP JP2014225005A patent/JP5855209B2/ja active Active
-
2015
- 2015-03-02 IL IL237507A patent/IL237507A0/en active IP Right Grant
-
2017
- 2017-06-05 PH PH12017501038A patent/PH12017501038B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501038A1 (en) | Novel radioimmunoconjugates and uses thereof | |
| PH12013500955A1 (en) | Spiro-oxindole mdm2 antagonists | |
| TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
| IL225471B (en) | Preparations for the prevention and treatment of cancer | |
| MX2011003473A (es) | Composiciones para el cuidado bucal. | |
| MX2019009621A (es) | Composiciones antitranspirantes y desodorantes. | |
| MX2020012426A (es) | Anticuerpos anti-cd38. | |
| GB201118656D0 (en) | New compounds | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| ZA201206302B (en) | Tooth whitening composition | |
| IL251083B (en) | Compounds and preparations for the treatment of cancer | |
| MX2016008226A (es) | Metodos para el cuidado oral prebiotico usando un sacarido. | |
| MX2012006434A (es) | Procesos para la preparacion de deferasirox, y polimorfos de deferasirox. | |
| EP2659879A4 (en) | HAIR TREATMENT AGENT COMPOSITION | |
| EP2601930A4 (en) | MEANS FOR INCREASING A BLEACHING EFFECT AND APPLYING THEREOF | |
| EP3406242B8 (en) | Tlr4 antagonist for use in the treatment of increased ammonia plasma levels | |
| GB201317815D0 (en) | Oral supplementation for the reversal of human hair canities | |
| PH12015501147A1 (en) | Synbiotic composition and use thereof | |
| MX2013008559A (es) | Derivados de leptina. | |
| MX2014003264A (es) | Uso cosmetico de hesperidina o un derivado de la misma en la prevencion y/o el tratamiento del olor corporal. | |
| TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists | |
| HU1000559D0 (en) | Pharmaceutical compositions for the treatment of osteoporosis and cancer | |
| IL222623A (en) | Preparations and kits for medical treatment | |
| GEP20135760B (en) | Medication for treating highmoritis and frontitis | |
| PH12013501424B1 (en) | Anti-cd38 antibodies |